MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Home
/
update
/
details

OncoLens Introduces Real-Time Oncology Patient Identification for Clinical Trials and Essential Services

NextEdge Admin

19 Sep 2024

2 min 25 sec

digital health solutions,clinical trials

OncoLens provides innovative digital health solutions aimed at delivering the right cancer treatment at the right time through three core pillars: data interoperability, multidisciplinary collaboration, and actionable informatics. By integrating data from various sources such as electronic medical records (EMR) and lab results, OncoLens identifies key patterns in patient clinical information. This integration generates real-time alerts for healthcare teams, helping identify patients who match clinical trial criteria, qualify for advanced therapies like CAR-T, or may have missed critical biomarker testing.

As cancer care becomes increasingly complex with the rise of hyper-targeted therapies and shifting guidelines, healthcare providers face challenges in ensuring patients receive optimal care. Large healthcare systems also grapple with patient leakage, where patients are referred out of the system rather than directed to in-house resources. Clinical trial enrollment is particularly affected, with Principal Investigators struggling to identify and enroll eligible patients.

OncoLens addresses these issues by utilizing AI, NLP, and its oncology-focused knowledge model to deliver timely reports and alerts. Its suite of tools, including OncoLens Conference and Collaborate, helps care teams track patients effectively and ensures timely sharing of information through tumor boards.

OncoLens’ solutions have proven effective in identifying patients who have missed essential germline or somatic testing, reducing time to treatment, and aligning with value-based healthcare models. With over 225 cancer centers in the U.S. and international collaborations, OncoLens also works with pharmaceutical and diagnostic companies through its Research Network to connect cancer centers with industry partners.